Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Raw Materials (2016 - 2025)

Historic Raw Materials for Adma Biologics (ADMA) over the last 10 years, with Q3 2025 value amounting to $87.8 million.

  • Adma Biologics' Raw Materials rose 5899.07% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 5899.07%. This contributed to the annual value of $60.5 million for FY2024, which is 1410.22% up from last year.
  • Latest data reveals that Adma Biologics reported Raw Materials of $87.8 million as of Q3 2025, which was up 5899.07% from $100.4 million recorded in Q2 2025.
  • Adma Biologics' Raw Materials' 5-year high stood at $100.4 million during Q2 2025, with a 5-year trough of $33.1 million in Q2 2021.
  • In the last 5 years, Adma Biologics' Raw Materials had a median value of $51.5 million in 2023 and averaged $55.2 million.
  • In the last 5 years, Adma Biologics' Raw Materials soared by 435.38% in 2023 and then surged by 7613.93% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Raw Materials stood at $36.8 million in 2021, then skyrocketed by 32.34% to $48.6 million in 2022, then grew by 8.95% to $53.0 million in 2023, then rose by 14.1% to $60.5 million in 2024, then surged by 45.25% to $87.8 million in 2025.
  • Its last three reported values are $87.8 million in Q3 2025, $100.4 million for Q2 2025, and $75.8 million during Q1 2025.